Notice: This company has been marked as potentially delisted and may not be actively trading. Merrimack Pharmaceuticals (MACK) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipTrends Merrimack Pharmaceuticals (NASDAQ:MACK) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage30.57%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$2.58 MNumber OfInsiders Selling(Last 12 Months)0 Get MACK Insider Trade Alerts Want to know when executives and insiders are buying or selling Merrimack Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MACK Insider Buying and Selling by Quarter Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Merrimack Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/28/2023Eric AndersenDirectorBuy857$13.35$11,440.95 12/26/2023Eric AndersenDirectorBuy48,693$13.15$640,312.95 12/7/2023Eric AndersenDirectorBuy101,050$12.85$1,298,492.50 11/17/2023Eric AndersenDirectorBuy300$12.50$3,750.00 11/14/2023Eric AndersenDirectorBuy50,170$12.50$627,125.00 (Data available from 1/1/2013 forward) MACK Insider Trading Activity - Frequently Asked Questions Who is on Merrimack Pharmaceuticals's Insider Roster? The list of insiders at Merrimack Pharmaceuticals includes Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy, and Ulrik B Nielsen. Learn more on insiders at MACK. What percentage of Merrimack Pharmaceuticals stock is owned by insiders? 30.57% of Merrimack Pharmaceuticals stock is owned by insiders. Learn more on MACK's insider holdings. Which Merrimack Pharmaceuticals insiders have been buying company stock? The following insiders have purchased MACK shares in the last 24 months: Ana Radeljevic ($49,996.68), Eric Andersen ($6,575,092.08), Gary L Crocker ($25,040.00), and Noah G Levy ($1,190,000.00). How much insider buying is happening at Merrimack Pharmaceuticals? Insiders have purchased a total of 648,892 MACK shares in the last 24 months for a total of $7,840,128.76 bought. More Insider Trading Tools from MarketBeat Related Companies IRWD Insider Trades EBS Insider Trades LXRX Insider Trades XOMA Insider Trades SGMO Insider Trades VNDA Insider Trades RIGL Insider Trades CDXS Insider Trades ACHV Insider Trades VSTM Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:MACK) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merrimack Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
